Consolidation in Regenerative Medicine Space?
Cytomedix Snags Cell Therapy Firm Aldagen for $16M in Stock
By Marie Powers
Thursday, February 9, 2012
Cytomedix Inc. drew attention to the regenerative medicine space Wednesday afternoon with the acquisition of privately held Aldagen Inc., which is developing autologous cell-based therapeutics for tissue repair and regeneration.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.